Literature DB >> 24550337

Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.

S Thee1, A J Garcia-Prats, H M McIlleron, L Wiesner, S Castel, J Norman, H R Draper, P L van der Merwe, A C Hesseling, H S Schaaf.   

Abstract

Limited data on fluoroquinolone pharmacokinetics and cardiac effects in children exist. Among 22 children receiving drug-resistant tuberculosis prophylaxis or treatment, serum concentrations following oral doses of levofloxacin (15 mg/kg of body weight) and ofloxacin (20 mg/kg) were lower than those expected from existing pediatric data, possibly due to differences in the formulations (crushed tablets). Drug exposures were lower than those in adults following standard doses and below the proposed pharmacodynamic targets, likely due to more rapid elimination in children. No QT prolongation was observed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24550337      PMCID: PMC3993207          DOI: 10.1128/AAC.02755-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

2.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

3.  Relative bioavailability of ofloxacin tablets in comparison to oral solution.

Authors:  V Malerczyk; M Verho; A Korn; R Rangoonwala
Journal:  Curr Med Res Opin       Date:  1987       Impact factor: 2.580

4.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

5.  Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; K R Sweeney
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920.

Authors:  L S Fridericia
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-10       Impact factor: 1.468

Review 7.  Fluoroquinolones, tuberculosis, and resistance.

Authors:  Amy Sarah Ginsburg; Jacques H Grosset; William R Bishai
Journal:  Lancet Infect Dis       Date:  2003-07       Impact factor: 25.071

8.  Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.

Authors:  Suvatna Chulavatnatol; Busba Chindavijak; Nitipatana Chierakul; Duangrat Klomsawat
Journal:  J Med Assoc Thai       Date:  2003-08

9.  Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.

Authors:  Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; P Venkatesan; L Sekar; S Kumar; O R Krishnarajasekhar; P Paramesh
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

10.  High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.

Authors:  James A Seddon; Anneke C Hesseling; Peter Godfrey-Faussett; H Simon Schaaf
Journal:  Thorax       Date:  2013-09-24       Impact factor: 9.139

View more
  21 in total

1.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

2.  Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.

Authors:  Hamidah Hussain; Courtney M Yuen; Amyn A Malik; Meredith B Brooks; Sara Siddiqui; Junaid Fuad; Charles A Peloquin; Farhana Amanullah; Maria Jaswal; Mercedes C Becerra
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.

Authors:  Sundari R Mase; John A Jereb; Daniel Gonzalez; Fatma Martin; Charles L Daley; Dorina Fred; Ann M Loeffler; Lakshmy R Menon; Sapna Bamrah Morris; Richard Brostrom; Terence Chorba; Charles A Peloquin
Journal:  Pediatr Infect Dis J       Date:  2016-04       Impact factor: 2.129

Review 4.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 5.  Pharmacokinetics of Second-Line Anti-Tubercular Drugs.

Authors:  Geetha Ramachandran
Journal:  Indian J Pediatr       Date:  2019-03-28       Impact factor: 1.967

6.  Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.

Authors:  Agibothu Kupparam Hemanth Kumar; Alok Kumar; Thiruvengadam Kannan; Rakesh Bhatia; Dipti Agarwal; Santosh Kumar; Rajeshwar Dayal; Sheo Pratap Singh; Geetha Ramachandran
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 7.  Safety Concerns Surrounding Quinolone Use in Children.

Authors:  Karisma Patel; Jennifer L Goldman
Journal:  J Clin Pharmacol       Date:  2016-03-28       Impact factor: 3.126

8.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

9.  Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

Authors:  Paolo Denti; Anneke C Hesseling; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Heather R Draper; H Simon Schaaf; Lubbe Wiesner
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

10.  Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anthony J Garcia-Prats; Heather R Draper; Lubbe Wiesner; Jana Winckler; Stephanie Thee; Kelly E Dooley; Rada M Savic; Helen M McIlleron; H Simon Schaaf; Anneke C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.